[go: up one dir, main page]

AU2001258859A1 - Pralmorelin-containing nasal drop preparations - Google Patents

Pralmorelin-containing nasal drop preparations

Info

Publication number
AU2001258859A1
AU2001258859A1 AU2001258859A AU5885901A AU2001258859A1 AU 2001258859 A1 AU2001258859 A1 AU 2001258859A1 AU 2001258859 A AU2001258859 A AU 2001258859A AU 5885901 A AU5885901 A AU 5885901A AU 2001258859 A1 AU2001258859 A1 AU 2001258859A1
Authority
AU
Australia
Prior art keywords
pralmorelin
alanyl
preparation
nasal drop
containing nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258859A
Inventor
Yasutomi Kato
Hirokuni Kogetsu
Kiyoshi Maruyama
Akiko Ochiai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of AU2001258859A1 publication Critical patent/AU2001258859A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The preparation for intranasal administration comprising D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylal anyl-L-lysinamide (pralmorelin) and/or an acid addition salt thereof as an active ingredient and water permits a marked increase in the in vivo absorption of pralmorelin and hence provides adequate efficacy even if it is administered in a small dose at a time. The preparation also allows pralmorelin to be dissolved in an increased amount, so it can be formulated pharmaceutically with great ease. It also high stability over time.
AU2001258859A 2000-05-29 2001-05-29 Pralmorelin-containing nasal drop preparations Abandoned AU2001258859A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-158676 2000-05-29
JP2000158676A JP3498041B2 (en) 2000-05-29 2000-05-29 Nasal formulation containing pralmorelin
PCT/JP2001/004503 WO2001091782A1 (en) 2000-05-29 2001-05-29 Pralmorelin-containing nasal drop preparations

Publications (1)

Publication Number Publication Date
AU2001258859A1 true AU2001258859A1 (en) 2001-12-11

Family

ID=18663108

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258859A Abandoned AU2001258859A1 (en) 2000-05-29 2001-05-29 Pralmorelin-containing nasal drop preparations

Country Status (7)

Country Link
US (1) US7008927B2 (en)
EP (1) EP1297838B1 (en)
JP (1) JP3498041B2 (en)
AT (1) ATE408413T1 (en)
AU (1) AU2001258859A1 (en)
DE (1) DE60135845D1 (en)
WO (1) WO2001091782A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4584331B2 (en) * 2005-03-11 2010-11-17 インデバス ファーマシューティカルズ、インク． Octreotide controlled-release formulation
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CA2672886C (en) * 2006-12-29 2015-02-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
KR20110025974A (en) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. Octreotide Implants Containing Release Agents
JP5622725B2 (en) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． Sustained delivery of exenatide and other polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
JPS63303931A (en) 1987-06-05 1988-12-12 Sumitomo Pharmaceut Co Ltd Growth hormone-releasing active substance preparation for nasal administration
IT1222395B (en) * 1987-07-30 1990-09-05 Pierrel Spa PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION INCLUDING THE HORMONE GHRH, A COLINERGIC AGONIST AND / OR A BILE SALT
JP3179538B2 (en) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト Aqueous solution of stable human calcitonin
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
EP0724885B1 (en) 1993-10-21 2002-03-13 Hisamitsu Pharmaceutical Co., Inc. Pernasal composition and pernasal preparation containing the same
JP2660484B2 (en) 1994-04-12 1997-10-08 株式会社ミドリ十字 Liquid preparation containing human urinary trypsin inhibitor
JPH1045619A (en) 1996-07-31 1998-02-17 Kaken Pharmaceut Co Ltd Oral preparation containing growth hormone secretagogue
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
AU2001274601A1 (en) * 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
JP2002053489A (en) * 2000-08-07 2002-02-19 Kaken Pharmaceut Co Ltd Muscle-building agent / Prevention / treatment agent for muscle attenuation

Also Published As

Publication number Publication date
EP1297838A1 (en) 2003-04-02
EP1297838A4 (en) 2003-07-09
US7008927B2 (en) 2006-03-07
EP1297838B1 (en) 2008-09-17
DE60135845D1 (en) 2008-10-30
US20030139347A1 (en) 2003-07-24
JP3498041B2 (en) 2004-02-16
JP2001335508A (en) 2001-12-04
ATE408413T1 (en) 2008-10-15
WO2001091782A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
CO5271759A1 (en) FORMULATION IN SOLUTION CONTAINING A MIXTURE OF SOLVENTS
GB9814172D0 (en) Formulation for inhalation
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2002017918A3 (en) Sustained release formulations for growth hormone secretagogues
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002019999A3 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
ITMI912024A1 (en) THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
EP1138323A3 (en) Resveratrol for the treatment of exfoliative eczema, acne or psoriasis
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
NZ507203A (en) Use of dexmedetomidine for ICU sedation
UA66812C2 (en) Drug formulation with controlled release of active ingredient
WO2002000166A3 (en) New compounds useful as antibacterial agents
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
WO2001051028A3 (en) Formulations and methods for administration of pharmacologically or biologically active compounds
DE50105710D1 (en) PHARMACEUTICAL BRAMULAR FORMULATION CONTAINING RAMIPRIL
AU2337900A (en) Preparation for warts
BE2016C017I2 (en)
GT199900171A (en) ORAL SERTRALINE CONCENTRATE.
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
EP0753309A2 (en) Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases